Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the value that NICE-recommended medicines bring to patient outcomes and the UK economy.

The National Institute for Health and Care Excellence (NICE) plays a vital role in securing access for National Health Service patients to innovative new medicines in a way that represents value to the taxpayer and supports a thriving United Kingdom life sciences sector. NICE is able to recommend the vast majority of new medicines for use by the NHS at prices that reflect the benefits that they bring to NHS patients and that are fair to all parties. Many thousands of NHS patients have benefitted from access to innovative new medicines as a result of NICE’s important work. The measures that we have announced this year as part of the Life Sciences Sector Plan and Regulation Action Plan will further accelerate patient access to new medicines whilst reducing burdens to industry.